April 20, 2018
Xstrahl is delighted to announce a UK SARRP user group workshop taking place on Wednesday June 27th following the 2018 ARR meeting at Queen’s University, Belfast. This is a joint event held by Xstrahl, Clinical and Translational Radiotherapy Research Working Group (CTRad) and Association for Radiation Research (ARR) to encourage collaboration across the UK small animal radiotherapy research platform (SARRP) user network.
April 5, 2018
Risk Capital Partners, the private equity firm chaired by Luke Johnson, today announces that it has bought a majority stake in Xstrahl, a medical devices business that designs and delivers effective clinical and research solutions to advance radiation oncology.
January 31, 2018
Xstrahl, the leader in X-Ray Technology for treatment of Superficial Skin conditions is pleased to offer the new RADiant therapy system to Physician’s in America. Representing the next generation of compact radiotherapy systems, RADiant’s dual modality provides patients with a pain free, non-surgical alternative for the treatment of non-melanoma skin cancers, keloids, and superficial lesions, especially those found in hard to reach, or sensitive facial regions.
January 10, 2018
Xstrahl today released an upgrade to its Concerto software streamlining the clinical workflow for the entire range of the Xstrahl systems. Concerto 2.0 provides a streamlined workflow, enhanced connectivity options and a treatment verification module.
January 4, 2018
The Xstrahl Group officially announced that Adrian Treverton has been promoted to Group CEO. This comes as the previous CEO, Martin Robinson retired in the new year after working for the company nearly 20 years. Adrian had more than 10 years of industry leadership experience before coming to Xstrahl, as an International sales manager in 2006. As Sales Director, he took the lead on building up Xstrahl’s distributor network and growing the US subsidiary, ultimately moving to the USA in 2011 to continue his work with the Life Science brand. In 2013 Adrian was appointed Chief Operations Officer and continued to build a strong team around him.
November 9, 2017
Following the supply of an Xstrahl 200 to the Island of Cuba, Xstrahl Medical has reached out to the rest of South America and Spanish speaking countries to solve the ever-present problem of skin cancer. Whilst pale skin is at a higher risk of skin cancer, the incidence rate of melanomas in the past two decades amongst Hispanic skin types has risen to epidemic proportions. Strong sun, coupled with poor safe sun knowledge has left many looking for a treatment that will not only successfully treat their skin cancer, but leave them scar free.
October 17, 2017
The RADiant System is a compact and ergonomic superficial X-Ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids. Utilising trusted and clinically proven low energy photons, in a dedicated treatment system the RADiant System provides a pain free, non-surgical alternative for the treatment of non-melanoma skin cancer and superficial lesions, especially those found in sensitive areas of the head and neck.
October 11, 2017
Xstrahl is delighted to announce the appointment of Kafait Ali to the Board of the Xstrahl Group. Kafait became a fellow of the ACCA in 2000 and has worked for a series of technology companies for over 12 years as both accountant and financial controller. Most recently, he worked for over 10 years in Buffalo Technology Europe where he was Chief Financial Officer for the European subsidiaries of this Japanese high-tech conglomerate. He gained a wealth of experience in international finance and group accounting.
July 3, 2017
It has become a good tradition for Xstrahl Medical to sponsor the Skin Cancer Radiotherapy Study Day at Norfolk and Norwich University Hospital, which this year is taking place on 5 August. The one day skin cancer radiotherapy course is for clinical oncology and dermatology trainees and practitioners, especially those specialising with the FRCR. The course includes concise lectures on principles of skin cancer management, management of difficult cases & practice session, mould room, treatment machine sessions and a mock examination for those preparing for the FRCR part II.
June 7, 2017
Action Radiotherapy is campaigning to improve patient access to advanced radiotherapy across the nation. They believe that every NHS patient should have access to the best radiotherapy options. Both Xstrahl Medical and Oncotherapy Resources (ORL) believe heavily in this cause, and together have given a sizable donation to the charity to help support them continue their fantastic work.
April 5, 2017
Xstrahl is pleased to announce the supply of the first superficial radiotherapy system – Xstrahl 200 to Havana, Cuba. The equipment was installed in early 2016 and has now been successfully treating Cuban cancer patients for the last 12 months.